# Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity

> **NCT01796548** · PHASE4 · TERMINATED · sponsor: **Janssen-Cilag Ltd.,Thailand** · enrollment: 17 (actual)

## Conditions studied

- Detrusor Function, Overactive

## Interventions

- **DRUG:** Oxybutinin Extended-Release

## Key facts

- **NCT ID:** NCT01796548
- **Lead sponsor:** Janssen-Cilag Ltd.,Thailand
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Slow rate of participant's enrollment
- **Last updated:** 2013-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01796548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01796548, "Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01796548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*